Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-09-01 Epub Date: 2024-09-17 DOI:10.1080/17474124.2024.2402358

Sandhya Patel, Alina Hasanain, Adam Fang, Mohammad Mahdi Khavandi, Trevor Mathias, Emil I Cohen, Vahid Etezadi, Saher S Sabri, Juan C Camacho, Hooman Yarmohammadi, Filip Banovac, Aiwu R He, Pejman Radkani, Peiman Habibollahi, Nariman Nezami

{"title":"Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma.","authors":"Sandhya Patel, Alina Hasanain, Adam Fang, Mohammad Mahdi Khavandi, Trevor Mathias, Emil I Cohen, Vahid Etezadi, Saher S Sabri, Juan C Camacho, Hooman Yarmohammadi, Filip Banovac, Aiwu R He, Pejman Radkani, Peiman Habibollahi, Nariman Nezami","doi":"10.1080/17474124.2024.2402358","DOIUrl":null,"url":null,"abstract":"Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 2nd most common primary liver malignancy. For nonsurgical candidates, the primary treatment option is systemic chemotherapy, which can be combined with locoregional therapies to enhance local control. Common intra-arterial locoregional therapies include transarterial hepatic embolization, conventional transarterial chemoembolization, drug-eluting bead transarterial chemoembolization, transarterial radioembolization with Yttrium-90 microspheres, and hepatic artery infusion. This article aims to review the latest literature on intra-arterial locoregional therapies for treating ICC.Areas covered: A literature search was conducted on PubMed using keywords: intrahepatic cholangiocarcinoma, intra-arterial locoregional therapy, embolization, chemoembolization, radioembolization, hepatic artery infusion, and immunotherapy. Articles from 2008 to 2024 were reviewed. Survival data from retrospective and prospective studies, meta-analyses, and clinical trials were evaluated.Expert opinion: Although no level I evidence supports the superiority of any specific intra-arterial therapy, there has been a shift toward favoring radioembolization. In our expert opinion, radioembolization may offer superior outcomes when performed by skilled operators with meticulous planning and personalized dosimetry, particularly for radiation segmentectomy or treating lobar/bilobar disease in appropriate candidates.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"505-519"},"PeriodicalIF":3.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2402358","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 2nd most common primary liver malignancy. For nonsurgical candidates, the primary treatment option is systemic chemotherapy, which can be combined with locoregional therapies to enhance local control. Common intra-arterial locoregional therapies include transarterial hepatic embolization, conventional transarterial chemoembolization, drug-eluting bead transarterial chemoembolization, transarterial radioembolization with Yttrium-90 microspheres, and hepatic artery infusion. This article aims to review the latest literature on intra-arterial locoregional therapies for treating ICC.

Areas covered: A literature search was conducted on PubMed using keywords: intrahepatic cholangiocarcinoma, intra-arterial locoregional therapy, embolization, chemoembolization, radioembolization, hepatic artery infusion, and immunotherapy. Articles from 2008 to 2024 were reviewed. Survival data from retrospective and prospective studies, meta-analyses, and clinical trials were evaluated.

Expert opinion: Although no level I evidence supports the superiority of any specific intra-arterial therapy, there has been a shift toward favoring radioembolization. In our expert opinion, radioembolization may offer superior outcomes when performed by skilled operators with meticulous planning and personalized dosimetry, particularly for radiation segmentectomy or treating lobar/bilobar disease in appropriate candidates.

查看原文本刊更多论文

肝内胆管癌的动脉内局部疗法。

简介肝内胆管癌（ICC）是第二大最常见的原发性肝脏恶性肿瘤。对于非手术治疗者，主要治疗方案是全身化疗，并可结合局部治疗以加强局部控制。常见的动脉内局部疗法包括经动脉肝栓塞、传统经动脉化疗栓塞、药物洗脱珠经动脉化疗栓塞、钇-90微球经动脉放射栓塞和肝动脉灌注。本文旨在综述治疗 ICC 的动脉内局部疗法的最新文献：使用关键词：肝内胆管癌、动脉内局部治疗、栓塞、化疗栓塞、放射栓塞、肝动脉灌注和免疫疗法，在PubMed上进行了文献检索。对 2008 年至 2024 年的文章进行了回顾。评估了来自回顾性和前瞻性研究、荟萃分析和临床试验的生存数据：专家意见：尽管没有一级证据支持任何特定的动脉内疗法具有优越性，但人们已开始倾向于放射栓塞疗法。我们的专家认为，如果由技术娴熟的操作人员通过精心策划和个性化剂量测定进行放射栓塞治疗，可能会取得更好的疗效，尤其是在进行放射分段切除术或治疗适合患者的肺叶/肺叶疾病时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.